Mobile

A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes who are also receiving Glimepiride and Metformin

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002612-10

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

(1) After 24 weeks, to assess the effect of the addition of treatment with MK- 3102 compared with the addition of placebo on A1C. (2) To assess the safety and tolerability of MK 3102.

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens